320 related articles for article (PubMed ID: 20212015)
21. Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT.
Wong KK; Sisson JC; Koral KF; Frey KA; Avram AM
AJR Am J Roentgenol; 2010 Sep; 195(3):730-6. PubMed ID: 20729453
[TBL] [Abstract][Full Text] [Related]
22. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma.
Mirallié E; Guillan T; Bridji B; Resche I; Rousseau C; Ansquer C; Bodet-Milin C; Curtet C; Carnaille B; Murat A; Charbonnel B; Kraeber-Bodéré F
Surgery; 2007 Dec; 142(6):952-8; discussion 952-8. PubMed ID: 18063081
[TBL] [Abstract][Full Text] [Related]
24. Role of [
Xu Q; Liu R; Wang J; Huang Y; Li S; Zhang L; Wang F
Nucl Med Biol; 2020; 88-89():34-43. PubMed ID: 32688289
[TBL] [Abstract][Full Text] [Related]
25. The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer.
Wang H; Fu HL; Li JN; Zou RJ; Gu ZH; Wu JC
Clin Imaging; 2009; 33(1):49-54. PubMed ID: 19135930
[TBL] [Abstract][Full Text] [Related]
26. The value of I-131 SPECT in the detection of recurrent differentiated thyroid cancer.
Geerlings JA; van Zuijlen A; Lohmann EM; Smit JW; Stokkel MP
Nucl Med Commun; 2010 May; 31(5):417-22. PubMed ID: 20154638
[TBL] [Abstract][Full Text] [Related]
27. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
Ma C; Wang X; Shao M; Zhao L; Jiawei X; Wu Z; Wang H
Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
[TBL] [Abstract][Full Text] [Related]
28. Postablation (131)I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer.
Ciappuccini R; Heutte N; Trzepla G; Rame JP; Vaur D; Aide N; Bardet S
Eur J Endocrinol; 2011 Jun; 164(6):961-9. PubMed ID: 21471170
[TBL] [Abstract][Full Text] [Related]
29. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
30. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer.
Shankar LK; Yamamoto AJ; Alavi A; Mandel SJ
J Nucl Med; 2002 Jan; 43(1):72-6. PubMed ID: 11801706
[TBL] [Abstract][Full Text] [Related]
31. Double-phase (131)I whole body scan and (131)I SPECT-CT images in patients with differentiated thyroid cancer: their effectiveness for accurate identification.
Wakabayashi H; Nakajima K; Fukuoka M; Inaki A; Nakamura A; Kayano D; Kinuya S
Ann Nucl Med; 2011 Nov; 25(9):609-15. PubMed ID: 21725630
[TBL] [Abstract][Full Text] [Related]
32. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma.
Nahas Z; Goldenberg D; Fakhry C; Ewertz M; Zeiger M; Ladenson PW; Wahl R; Tufano RP
Laryngoscope; 2005 Feb; 115(2):237-43. PubMed ID: 15689742
[TBL] [Abstract][Full Text] [Related]
33. The added value of SPECT/spiral CT in patients with equivocal bony metastasis from hepatocellular carcinoma.
Zhang Y; Shi H; Li B; Cai L; Gu Y; Xiu Y
Nuklearmedizin; 2015; 54(6):255-61. PubMed ID: 26615876
[TBL] [Abstract][Full Text] [Related]
34. Frequent visualization of thyroglossal duct remnant on post-ablation 131I-SPECT/CT and its clinical implications.
Lee M; Lee YK; Jeon TJ; Chang HS; Kim BW; Lee YS; Park CS; Ryu YH
Clin Radiol; 2015 Jun; 70(6):638-43. PubMed ID: 25824279
[TBL] [Abstract][Full Text] [Related]
35. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
[TBL] [Abstract][Full Text] [Related]
36. The value of simultaneous co-registration of 99mTc- MDP and 131Iodine in metastatic differentiated thyroid carcinoma.
Kotb MH; Omar W; El-Maghraby T; El-Bedwihy M; El-Tawdy M; Mustafa H; Al-Nahhas A
Nucl Med Rev Cent East Eur; 2007; 10(2):98-105. PubMed ID: 18228214
[TBL] [Abstract][Full Text] [Related]
37. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
38. The clinical significance of remnant thyroid tissue in thyroidectomized differentiated thyroid cancer patients on
Wang F; Nie H; Li W; Zhang R; Li W
BMC Med Imaging; 2021 May; 21(1):78. PubMed ID: 33964885
[TBL] [Abstract][Full Text] [Related]
39. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
[TBL] [Abstract][Full Text] [Related]
40. [The value of multimodal imaging by single photon emission computed tomography associated to X ray computed tomography (SPECT-CT) in the management of differentiated thyroid carcinoma: about 156 cases].
Mhiri A; El Bez I; Slim I; Meddeb I; Yeddes I; Ghezaiel M; Gritli S; Ben Slimène MF
Tunis Med; 2013 Oct; 91(10):589-93. PubMed ID: 24281999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
